Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory indolent non-Hodgkin lymphoma from the ongoing phase 1 CaDAnCe-101 study

View Full Paper
Ask AI
Bookmark
Share

Authors

DYDok Hyun YoonEMEric MouPZPier Luigi Zinzani

Discussion

Loading...

Member takes

Overview

Phase 1 trial shows BGB-16673 achieves 41.2% overall response rate in follicular lymphoma, indicating efficacy in advanced disease.

Key Points

  • Overall response rate for follicular lymphoma was 41.2% at 12 weeks, with some responses lasting over 6 months.
  • Treatment-emergent adverse events occurred in 87.5% of patients with follicular lymphoma, with grade ≥3 seen in 25%.
  • Observational analysis of patients on a novel BTK degrader shows a median time to first response of 2.7 months for follicular lymphoma.
  • BGB-16673 is tolerable and may provide clinically significant benefits, despite occurring in heavily pretreated populations.

Cite This Study

Yoon et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9b3https://doi.org/10.1182/blood-2025-3584
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study2025 · 1 citations
  2. 2CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies2025 · 2 citations
  3. 3Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia from the ongoing phase 1 CaDAnCe-101 study2025 · 2 citations
  4. 4CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma2025 · 1 citations
  5. 5CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor2025